Phoenix Financial Ltd. Increases Stake in Novo Nordisk A/S $NVO

Phoenix Financial Ltd. increased its position in Novo Nordisk A/S (NYSE:NVO) by 11.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 122,154 shares of the company’s stock after acquiring an additional 12,828 shares during the quarter. Phoenix Financial Ltd.’s holdings in Novo Nordisk A/S were worth $6,213,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth about $25,000. WealthCollab LLC increased its holdings in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $28,000. Maseco LLP purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: New clinical data for oral Wegovy and higher-dose Wegovy showed strong weight-loss results, improved mobility, and broader benefits, reinforcing Novo Nordisk’s obesity-growth story and helping offset worries about slowing momentum. Novo Nordisk (NVO) Announces Positive Early Response Data from Oral Wegovy (25 mg) Trial
• Positive Sentiment: The company’s latest Q1 results beat expectations and it raised its 2026 outlook, which supports the case that newer product launches are still driving sales growth. Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly’s Growing Pressure?
• Positive Sentiment: Investor-friendly commentary and bullish takes continue to highlight Novo Nordisk as undervalued relative to its long-term growth potential, especially if new indications expand its blockbuster franchise. Best Healthcare Stocks to Buy in 2026
• Neutral Sentiment: Several market commentaries and analyst forecast pages were published on NVO, but they appear to be mostly rating/price-target updates rather than new company-specific catalysts. Novo Nordisk A/S (NVO) stock forecast and price target
• Neutral Sentiment: Novo Nordisk also disclosed gifted share transactions linked to CFO associates, which is worth noting but does not by itself appear to change the company’s fundamentals. Novo Nordisk Discloses Gifted Share Transactions Linked to CFO Associates
• Negative Sentiment: Bearish commentary argues Novo Nordisk’s valuation may still be a value trap, and competition from Eli Lilly’s expanding GLP-1 pipeline remains a real threat to obesity-market share. Novo Nordisk: Why I Won’t Upgrade

Analyst Ratings Changes

Several brokerages recently weighed in on NVO. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Down 2.7%

Shares of NYSE NVO opened at $45.82 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $204.60 billion, a price-to-earnings ratio of 10.76, a PEG ratio of 4.19 and a beta of 0.77. The business has a 50-day moving average of $39.61 and a 200-day moving average of $46.71.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion during the quarter. Sell-side analysts expect that Novo Nordisk A/S will post 3.47 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.